Samsung Bioepis begins Phase 3 trial for SB27 biosimilar referencing Keytruda for non-small cell lung cancer.

Samsung Bioepis begins Phase 3 trial for SB27, a biosimilar referencing Keytruda (pembrolizumab) for non-small cell lung cancer. The randomized, double-blind, parallel group study in various countries aims to compare SB27's efficacy, safety, pharmacokinetics, and immunogenicity to Keytruda. This follows the successful Phase 1 trial initiation in February 2024.